Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Key Stats

• Today's Range: $2.64 to $2.68
• 50-Day Range: $2.45 to $2.66
• 52-Week Range: $1.04 to $7.18
• Volume: 2.81 million shs
• Average Volume: 418,678 shs
• Market Capitalization: $125.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.30
• Consensus Rating: Hold

Kinnate Biopharma Stock Analysis - MarketRank™

Kinnate Biopharma scored higher than 29% of companies evaluated by MarketBeat, and ranked 827th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Kinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kinnate Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.51) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kinnate Biopharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KNTE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kinnate Biopharma does not currently pay a dividend.

Dividend Growth

Kinnate Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.81

Short Interest

There is no current short interest data available for KNTE.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for KNTE on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.89% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KNTE Stock Analysis - Frequently Asked Questions

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.73).

When did Kinnate Biopharma IPO?

Kinnate Biopharma (KNTE) raised $170 million in an IPO on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

What other stocks do shareholders of Kinnate Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG).

Company Calendar

• Last Earnings: 5/11/2023
• Today: 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KNTE
• CUSIP: N/A
• CIK: 1797768
• Web: www.kinnate.com
• Phone: 858-299-4699
• Fax: N/A
• Employees: 84
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.30
• High Stock Price Target: $2.59
• Low Stock Price Target: $2.00
• Potential Upside/Downside: -13.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-116,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.31%
• Return on Assets: -54.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.80
• Quick Ratio: 10.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.06 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 47,220,000
• Free Float: 27,532,000
• Market Cap: $125.13 million
• Optionable: Optionable
• Beta: 1.38